Status:
TERMINATED
Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine
Lead Sponsor:
University of California, San Francisco
Conditions:
Rheumatic Diseases
Eligibility:
All Genders
Up to 120 years
Phase:
NA
Brief Summary
Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, a...
Eligibility Criteria
Inclusion
- All providers that prescribed hydroxychloroquine in the year previous to the intervention start date in rheumatology and dermatology clinics
Exclusion
- Inactive providers in rheumatology and dermatology clinics
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04310462
Start Date
February 1 2017
End Date
February 28 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143